Navigation Links
Delcath Systems to Report Third Quarter Progress and Conduct Conference Call
Date:10/28/2011

ommercial sale of its system in the United States. For more information, please visit the Company's website at http://www.delcath.com/.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales, if any, for the Hepatic CHEMOSAT delivery system in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for the CHEMOSAT system, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities, and uncertainties relating to the impact, if any, of being added to the Russell Microcap
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Schedules Delcath Pre-New Drug Application Meeting Date
2. Delcath Announces Completion of Regulatory Notification Process in New Zealand
3. Delcath Announces Updated Efficacy Results From Phase 3 Trial of Chemosaturation for Melanoma Metastases in the Liver Presented at European Multidisciplinary Cancer Congress
4. Delcath to Present at the JMP Securities Healthcare Conference on September 28, 2011
5. Delcath Systems, Inc. Hosts Symposium on Chemosaturation at CIRSE Annual Meeting
6. Delcath Announces Top-Line Results From Metastatic Colorectal Cohort in Phase II Trial of Chemosaturation System
7. Delcath Announces Encouraging Top-Line Results From Hepatobiliary Cohort in Phase II Trial of Chemosaturation System
8. Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011
9. Delcath Systems to Report Second Quarter Progress Update and Conduct Conference Call
10. Delcath Systems, Inc. Announces the Completion of Common Stock Offering
11. Delcath Systems, Inc. Announces the Sale of 5,000,000 Shares of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , and MARSEILLE, France , ... , Exclusive global license from University of Tokyo enables ... sequencing (NGS) gene panels, for blood cancers  ... test, indicate favorable prognosis for patients with bone marrow ... potential for developing companion diagnostics to guide treatment with ...
(Date:7/24/2014)... Ohio, July 24, 2014  Mettler-Toledo International Inc. (NYSE: ... for 2014.  Provided below are the highlights: ... the quarter compared with the prior year. Reported sales ... , Net earnings per diluted share as reported ... quarter of 2013. Adjusted EPS was $2.57, an increase ...
(Date:7/24/2014)... , July 24, 2014 Omnicell, Inc. ... of medication and supply management solutions and analytics ... Thursday, July 31, to discuss the Company,s Second ... Second Quarter 2014 earnings conference call and webcastWhen: ... , Randall Lipps, chairman, president and chief executive ...
Breaking Medicine Technology:QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2
... Company (NYSE: PG ) today announced that three ... (SEAP). The new members are: Caroline Hermans, ... Howard Frumkin – Dean, School of the Public Health at ... California Environmental Protection Agency "With key ...
... Fujirebio Diagnostics, Inc., today announced that the U.S. Food and ... CYFRA 21-1™ EIA assay to monitor disease progression during the ... is the first biomarker assay kit to be cleared by ... cancer. "The clearance of the CYFRA 21-1 assay ...
Cached Medicine Technology:P&G Welcomes New Members to U.S. Sustainability Expert Advisory Panel 2P&G Welcomes New Members to U.S. Sustainability Expert Advisory Panel 3Fujirebio Diagnostics, Inc. Receives FDA 510 (k) Clearance for First Biomarker to Monitor Lung Cancer 2
(Date:7/25/2014)... July 25, 2014 According to the ... Wafer, Devices, Applications, and Geography - Analysis & Forecast ... substrate is expected to reach $3.01 Billion by 2020 ... Technology Market for devices is expected to reach $6.17 ... includes an in-depth analysis of application and geography. , ...
(Date:7/25/2014)... CA (PRWEB) July 25, 2014 Agoura Hills ... special promotion on Zoom Whitening. Zoom Whitening is one of ... only available through a dental professional. This light-assisted treatment uses ... the structure of the tooth to break up stains that ... effective on coffee, tea, wine, soft drink and tobacco stains. ...
(Date:7/25/2014)... olefin is an olefin or an alkene with a double ... carbon chain, or between the 1st and 2nd carbon atom. ... (or normal). The alpha olefin market is a vital market, ... polyethylene co-monomers and synthetic lubricants, across a wide range of ... markets for alpha olefins; however, Asia-Pacific has emerged as a ...
(Date:7/25/2014)... inconclusive cancer screening test results among some patients is ... Gareen et al, published July 25 in Cancer ... false positive or other results of computed tomography (CT) ... by some in the medical community. , "Unsubstantiated ... be put to rest and not continue to delay ...
(Date:7/25/2014)... A report released by the Juvenile Diabetes ... 2013 (July 1, 2012- June 30, 2013). , Outside of ... is the largest single funder of type 1 diabetes research ... with most of the top research centers. There is ... 1 diabetes in the near future. , Since the 2008 ...
Breaking Medicine News(10 mins):Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 5Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 6Health News:Agoura Hills Dentist, Dr. Amir Choroomi, is Now Offering a Promotion on Zoom Whitening 2Health News:Europe Alpha Olefins Market is Expected to Reach $1,958 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Alpha Olefins Market is Expected to Reach $1,958 Million in 2018 - New Report by MicroMarket Monitor 3Health News:ACR statement on cancer study regarding patient anxiety from CT lung cancer screening 2Health News:Report: JDRF 2013 Annual Research Spending Down by $50 million 2
... N.M., April 15 Civility Mutual, based in,Santa ... and only membership,organization to offer education, training and ... residency directors with the,educational tools and assessments their ... the ACGME Outcomes Project., "Civility in health ...
... Utrecht, The Netherlands April 15, 2008 ... 60 percent increased risk of developing pneumonia compared ... first week following prescription and decreases gradually thereafter. ... American Geriatrics Society. , Antipsychotic drugs are frequently ...
... HUNTSVILLE, Ala., April 15 Open Biosystems, ... science research,tools for drug discovery, today announced ... pools for multiplexed RNAi screens. This,novel offering ... and,the ability to rapidly screen through thousands ...
... 15 /Xinhua-PRNewswire-FirstCall/ -- CNinsure,Inc. CISG, a leading ... China, today announced the signing of an ... Co., Ltd ("Minsheng Life,Insurance")., According to ... with Minsheng Life Insurance at both the ...
... April 15, 2008 -- Results of a phase ... high-dose, high-frequency subcutaneous Rebif (interferon beta-1a) provide clinical evidence ... to 30 months of continued therapy in patients with ... in the April 2008 issue of the Current Medical ...
... practical for treating human diseases, researchers must master the ... The Childrens Hospital of Philadelphia have advanced delivery techniques ... to a variety of gene therapy vectors and can ... at a disease site. , In an animal study, ...
Cached Medicine News:Health News:New Health Care Company to Offer Training and CMEs on Physician - Patient Communications and Helps Fulfill ACGME Requirements 2Health News:Open Biosystems Launches Decode RNAi Viral Screening Pools for Low-Cost Genome-Scale RNAi Screens 2Health News:CNinsure Enters Into Strategic Partnership With Minsheng Life Insurance 2Health News:CNinsure Enters Into Strategic Partnership With Minsheng Life Insurance 3Health News:Study shows that high-dose, high-frequency interferon produces no additional benefit 2Health News:In blood vessel stents, innovative materials allow better control, delivery of gene therapy 2Health News:In blood vessel stents, innovative materials allow better control, delivery of gene therapy 3
... for this age group?, ,Babies and young ... of an MDI. , ,Dry powder devices ... achieve efficiency. , ,Traditional nebulizers have high ... often used for this age group are inefficient ...
... Compact Compressor is for active patients who ... and everywhere. The compressor is small and ... optionsworldwide AC compatibility (100 to 240V), 12 ... the freedom to take aerosol treatments away ...
... Compact sporty design and ... XL the product of choice ... and performance. The CompAir XL ... cord storage compartment and a ...
... The 50 psi MaxiCompressor, ... designed to run 24 hours ... week. It features a tamper-proof ... against unintentional increases or decreases ...
Medicine Products: